Cargando…

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival

BACKGROUND: Patients treated with immune checkpoint inhibitors (ICIs) may experience pseudoprogression, which can be classified as progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and could lead to inappropriate treatment discontinuation. Immune-response criter...

Descripción completa

Detalles Bibliográficos
Autores principales: Manitz, Juliane, D'Angelo, Sandra P, Apolo, Andrea B, Eggleton, S Peter, Bajars, Marcis, Bohnsack, Oliver, Gulley, James L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886415/
https://www.ncbi.nlm.nih.gov/pubmed/35228264
http://dx.doi.org/10.1136/jitc-2021-003302
_version_ 1784660659674284032
author Manitz, Juliane
D'Angelo, Sandra P
Apolo, Andrea B
Eggleton, S Peter
Bajars, Marcis
Bohnsack, Oliver
Gulley, James L
author_facet Manitz, Juliane
D'Angelo, Sandra P
Apolo, Andrea B
Eggleton, S Peter
Bajars, Marcis
Bohnsack, Oliver
Gulley, James L
author_sort Manitz, Juliane
collection PubMed
description BACKGROUND: Patients treated with immune checkpoint inhibitors (ICIs) may experience pseudoprogression, which can be classified as progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and could lead to inappropriate treatment discontinuation. Immune-response criteria were developed to better capture novel response patterns seen with ICIs. METHODS: We pooled data from 1765 patients with 12 types of advanced solid tumors treated with avelumab (an anti-programmed death ligand 1 (PD-L1) monoclonal antibody) monotherapy in the JAVELIN Solid Tumor and JAVELIN Merkel 200 trials, conducted a comparative analysis of tumor assessments by investigators according to RECIST 1.1 and immune-related RECIST (irRECIST), and evaluated the correlation between progression-free survival (PFS) and overall survival (OS). RESULTS: In total, 147 patients (8.3%) had a best overall response (BOR) of PD by RECIST 1.1 but had immune-related disease control by irRECIST (defined as immune-related BOR (irBOR) of immune-related stable disease or better). This discordance was seen irrespective of PD-L1 status and observed across all tumor types. Overall, PFS and immune-related PFS showed similar imputed rank correlations with OS. CONCLUSIONS: The use of irRECIST identified a subset of patients with a BOR of PD by RECIST 1.1 but an irBOR of immune-related disease control by irRECIST with a distinctive survival curve, thereby providing more clinically relevant information than RECIST 1.1 alone. However, as a surrogate endpoint for OS in the whole population, immune-related PFS by irRECIST did not show improved predictive value compared with PFS by RECIST 1.1.
format Online
Article
Text
id pubmed-8886415
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-88864152022-03-17 Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival Manitz, Juliane D'Angelo, Sandra P Apolo, Andrea B Eggleton, S Peter Bajars, Marcis Bohnsack, Oliver Gulley, James L J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: Patients treated with immune checkpoint inhibitors (ICIs) may experience pseudoprogression, which can be classified as progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and could lead to inappropriate treatment discontinuation. Immune-response criteria were developed to better capture novel response patterns seen with ICIs. METHODS: We pooled data from 1765 patients with 12 types of advanced solid tumors treated with avelumab (an anti-programmed death ligand 1 (PD-L1) monoclonal antibody) monotherapy in the JAVELIN Solid Tumor and JAVELIN Merkel 200 trials, conducted a comparative analysis of tumor assessments by investigators according to RECIST 1.1 and immune-related RECIST (irRECIST), and evaluated the correlation between progression-free survival (PFS) and overall survival (OS). RESULTS: In total, 147 patients (8.3%) had a best overall response (BOR) of PD by RECIST 1.1 but had immune-related disease control by irRECIST (defined as immune-related BOR (irBOR) of immune-related stable disease or better). This discordance was seen irrespective of PD-L1 status and observed across all tumor types. Overall, PFS and immune-related PFS showed similar imputed rank correlations with OS. CONCLUSIONS: The use of irRECIST identified a subset of patients with a BOR of PD by RECIST 1.1 but an irBOR of immune-related disease control by irRECIST with a distinctive survival curve, thereby providing more clinically relevant information than RECIST 1.1 alone. However, as a surrogate endpoint for OS in the whole population, immune-related PFS by irRECIST did not show improved predictive value compared with PFS by RECIST 1.1. BMJ Publishing Group 2022-02-28 /pmc/articles/PMC8886415/ /pubmed/35228264 http://dx.doi.org/10.1136/jitc-2021-003302 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical/Translational Cancer Immunotherapy
Manitz, Juliane
D'Angelo, Sandra P
Apolo, Andrea B
Eggleton, S Peter
Bajars, Marcis
Bohnsack, Oliver
Gulley, James L
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
title Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
title_full Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
title_fullStr Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
title_full_unstemmed Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
title_short Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
title_sort comparison of tumor assessments using recist 1.1 and irrecist, and association with overall survival
topic Clinical/Translational Cancer Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886415/
https://www.ncbi.nlm.nih.gov/pubmed/35228264
http://dx.doi.org/10.1136/jitc-2021-003302
work_keys_str_mv AT manitzjuliane comparisonoftumorassessmentsusingrecist11andirrecistandassociationwithoverallsurvival
AT dangelosandrap comparisonoftumorassessmentsusingrecist11andirrecistandassociationwithoverallsurvival
AT apoloandreab comparisonoftumorassessmentsusingrecist11andirrecistandassociationwithoverallsurvival
AT eggletonspeter comparisonoftumorassessmentsusingrecist11andirrecistandassociationwithoverallsurvival
AT bajarsmarcis comparisonoftumorassessmentsusingrecist11andirrecistandassociationwithoverallsurvival
AT bohnsackoliver comparisonoftumorassessmentsusingrecist11andirrecistandassociationwithoverallsurvival
AT gulleyjamesl comparisonoftumorassessmentsusingrecist11andirrecistandassociationwithoverallsurvival